# Oritavancin (Orbactiv / Kimyrsa)

> Single-dose lipoglycopeptide for acute bacterial skin and skin structure infections.

Source: https://peptides.cafe/peptide/oritavancin
Category: Lipoglycopeptide · Antibiotic
Tag: FDA-Approved · Antibiotic

## Mechanism
Semisynthetic lipoglycopeptide derivative of chloroeremomycin that inhibits cell wall synthesis (transglycosylation, transpeptidation) and disrupts membrane integrity in Gram-positive bacteria including MRSA.

## Research areas
- Acute bacterial skin and skin structure infections (ABSSSI)

## Common research protocols
- Single IV dose: 1200 mg IV over 1–3 hours as a single dose.

## Study summaries
- "SOLO trials" — NEJM (2014): Single dose non-inferior to 7–10 days of vancomycin in ABSSSI.

## Considerations
- FDA-approved.
- Artifactually elevates aPTT/PT for up to 48 hours; avoid unfractionated heparin for 48h.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.